Membrane proteinase 3 (mPR3) expression on neutrophils is not increased in localised Wegener's granulomatosis (WG) and Churg-Strauss syndrome (CSS)

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  Holle, Julia U ^a   Wu, Q J ^a   Moosig, Frank ^a   Gross, Wolfgang L ^a   Csernok, Elena ^a  

^a Klinikum Bad Bramstedt   (Germany)

Author keywords

Churg Strauss syndrome; Generalised Wegener's granulomatosis; Localised Wegener's granulomatosis; Membrane PR3 expression; Neutrophils

Indexed keywords

CD63 ANTIGEN; MEMBRANE PROTEINASE 3; MYELOBLASTIN; UNCLASSIFIED DRUG; AUTOANTIGEN; EPITOPE; FIBRINOGEN RECEPTOR; LEUKOCYTE ANTIGEN; LYSOSOMAL PROTEIN GP53; MEMBRANE PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL SURFACE; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENERALIZED WEGENER GRANULOMATOSIS; HUMAN; HUMAN CELL; LOCALIZED WEGENER GRANULOMATOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS; ENZYMOLOGY; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; BLOOD; CELL ISOLATION; CORRELATION ANALYSIS; DAS28; HEALTH STATUS; HUMAN TISSUE; IMMUNOPATHOGENESIS; PROTEIN LOCALIZATION; SEPARATION TECHNIQUE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; AUTOANTIGENS; CHURG-STRAUSS SYNDROME; EPITOPES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYELOBLASTIN; NEUTROPHILS; PLATELET MEMBRANE GLYCOPROTEINS; SEVERITY OF ILLNESS INDEX; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 77954574965     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. TSCHOPP J, LUDEMANN J, UTECHT B, GROSS WL: Wegener's autoantigen decoded. Nature 1990; 346: 520.
2. PHAM CT: Neutrophil serine proteases: specific regulators of inflammation. Nat Reviews Immunol 2006; 6: 541-50.
3. CSERNOK E, ERNST M, SCHMITT W, BAINTON DF, GROSS WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244-50.
4. SCHREIBER A, BUSJAHN A, LUFT C, KETTRITZ R: Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14: 68-75.
5. HALBWACHS-MECCARELI L, BESSOU G, LESAVRE P, LOPEZ S, WITKO-SARSAT V: Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett 1995; 374: 29-33.
6. WITKO-SARSAT V, LESAVRE P, LOPEZ S et al.: A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999; 10: 1224-33.
7. MULLER KOBOLD AC, KALLENBERG CGM, COHEN TERVAERT JW: Leukocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br J Rheumatol 1998; 37: 901-7.
8. RAROK AA, STEGEMAN CA, LIMBURG PC, KALLENBERG CG: Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13: 2232-8.
9. CSERNOK E, AI M, GROSS WL et al.: Wegener's autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 2006; 107: 4440-8.
10. VAN ROSSUM AP, HUITEMA MG, STEGEMAN CA et al.: Standardised assessment of membrane proteinase 3 expression. Analysis in ANCA-associated vasculitis and controls. Ann Rheum Dis 2007; 66: 1350-5.
11. MATSUMOTO T, KANEKO T, WADA H et al.: Proteinase 3 expression on neutrophil membranes from patients with infectious disease. Shock 2006; 26; 128-33.
12. HARPER L, COCKWELL P, ADU D, SAVAGE CO: Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int 2001; 59: 1729-38.
13. CHOI HK, LAMPRECHT P, NILES JL, GROSS WL, MERKEL PA: Subacute bacterial endocarditis with positive cytoplasmatic antieutrophil antibodies and anti-proteinase-3 antibodies. Arthritis Rheum 2000; 43: 226-31.
14. CSERNOK E, HOLLE JU, GROSS WL: Proteinase-3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis. Clin Exp Rheumatol 2008; 26 (Suppl. 49): S112-117.
15. HELLMICH B, FLOSSMANN O, GROSS WL et al.: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-17.
16. CARRINGTON CB, LIEBOW AA: Limited form of angiitis and granulomatosis of Wegener's type. Am J Med 1966; 41: 497-527.
17. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
18. REINHOLD-KELLER E, DE GROOT K, RUDERT H et al.: Response to trimethoprim/sulfomethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996; 89: 15-23.
19. JENNETTE JC, FALK RJ, ANDRASSY K et al.; Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
20. LEAVITT RY, FAUCI AS, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
21. MASI AT, HUNDER GG, LIE JT et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-100.
22. MUKHTYAR C, LEE R, BROWN D et al.: Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-32.
23. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
24. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
25. VAN DER HEIJDE DM, VAN'T HOF M, VAN RIEL PL, VAN DE PUTTE LB: Development of a disease acitivity score based on judgement in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
26. MOSCA M, BENCIVELLI W, VITALI C, CARRAI P, NERI P, BOMBARDIERI S: The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000; 9: 445-50.